Dr. Hu brings more than 20 years of experience in drug discovery, operational management, and business development. He previously held senior executive roles at WuXi AppTec, where he oversaw a wide variety of project collaborations with over 30 multinational corporations and biotech companies. Prior to that, he conducted small-molecule drug R&D in neurology, oncology, and inflammation at Merck and Amgen in the US.

Before founding SciBrunch Therapeutics, Dr. Hu served as co-founder and CEO of Usynova Pharmaceuticals. Under his leadership, the company successfully pivoted from protein therapeutics to innovative small-molecule drug discovery within three years. He built a highly productive research team that developed UA022—a preclinical oral inhibitor of KRAS G12D— and led its exclusive global out-licensing to AstraZeneca in 2023.

Dr. Hu earned his PhD in organic synthetic chemistry from Boston University and completed postdoctoral research under Nobel Laureate Professor E. J. Corey at Harvard University. He also holds an EMBA from China Europe International Business School (CEIBS).

Dr. Zhang is a distinguished medicinal chemist with nearly 20 years experience in small-molecule drug discovery. Prior to founding SciBrunch Therapeutics, he served as Vice President at WuXi AppTec, delivering 30+ preclinical candidates with distinct competitive advantages to domestic and global partners.

Over the past 15 years, he has directed over 20 oncology inhibitor programs, successfully driving multiple assets into clinical trials. His drug-hunting portfolio heavily emphasizes high-value precision oncology targets, featuring deep expertise across receptor tyrosine kinases (RTKs) and the RAS pathway—including KRAS G12D, KRAS G12C, panKRAS, and panRAS inhibitors.

Dr. Zhang earned his MS from Nankai University and his PhD in Organic Chemistry from Lehigh University, followed by postdoctoral research at the University of Utah. A prolific innovator, his scientific contributions include over 300 international patents as an inventor and more than 20 peer-reviewed publications advancing medicinal chemistry.

Dr. Hu brings more than 20 years of experience in drug discovery, operational management, and business development. He previously held senior executive roles at WuXi AppTec, where he oversaw a wide variety of project collaborations with over 30 multinational corporations and biotech companies. Prior to that, he conducted small-molecule drug R&D in neurology, oncology, and inflammation at Merck and Amgen in the US.

Before founding SciBrunch Therapeutics, Dr. Hu served as co-founder and CEO of Usynova Pharmaceuticals. Under his leadership, the company successfully pivoted from protein therapeutics to innovative small-molecule drug discovery within three years. He built a highly productive research team that developed UA022—a preclinical oral inhibitor of KRAS G12D— and led its exclusive global out-licensing to AstraZeneca in 2023.

Dr. Hu earned his PhD in organic synthetic chemistry from Boston University and completed postdoctoral research under Nobel Laureate Professor E. J. Corey at Harvard University. He also holds an EMBA from China Europe International Business School (CEIBS).

Dr. Zhang is a distinguished medicinal chemist with nearly 20 years experience in small-molecule drug discovery. Prior to founding SciBrunch Therapeutics, he served as Vice President at WuXi AppTec, delivering 30+ preclinical candidates with distinct competitive advantages to domestic and global partners.

Over the past 15 years, he has directed over 20 oncology inhibitor programs, successfully driving multiple assets into clinical trials. His drug-hunting portfolio heavily emphasizes high-value precision oncology targets, featuring deep expertise across receptor tyrosine kinases (RTKs) and the RAS pathway—including KRAS G12D, KRAS G12C, panKRAS, and panRAS inhibitors.

Dr. Zhang earned his MS from Nankai University and his PhD in Organic Chemistry from Lehigh University, followed by postdoctoral research at the University of Utah. A prolific innovator, his scientific contributions include over 300 international patents as an inventor and more than 20 peer-reviewed publications advancing medicinal chemistry.